Search results for "Lisp"

showing 10 items of 87 documents

Preservation of dendritic cell function upon labeling with amino functionalized polymeric nanoparticles.

2010

Dendritic cells (DCs) are key players in eliciting immunity against antigens, therefore making them the focus of many investigations on immune responses in infections, cancer and autoimmune diseases. Nanosized materials have just recently been investigated for their use as carriers of antigens and as labeling agents for DCs. For this later use nanoparticles should be non-toxic and should most importantly not alter the physiological functions of DCs. Here we demonstrate that by the use of polymeric fluorescent nanoparticles as synthesized by the miniemulsion process immature DCs (iDCs) can be efficiently labeled intracellularly. Amino functionalized nanoparticles are more effective than carb…

CD4-Positive T-LymphocytesMaterials scienceBiophysicsCD11cchemical and pharmacologic phenomenaBioengineeringCD8-Positive T-LymphocytesFlow cytometryBiomaterialsCell therapyImmune systemAntigenmedicineHumansCells CulturedMicroscopy Confocalmedicine.diagnostic_testELISPOThemic and immune systemsDendritic cellDendritic CellsFlow CytometryCell biologyMechanics of MaterialsImmunologyCeramics and CompositesNanoparticlesPolystyrenesCD80Biomaterials
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

2021

Abstract Purpose: Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by characteristic mutations. Some of these characteristic mutations have shown to generate immunogenic neoepitopes suitable for targeted immunotherapy. Experimental Design: Using peptide-based ELISpot assays, we screened for potential recurrent glioma neoepitopes in MHC-humanized mice. Following vaccination, droplet-based single-cell T-cell receptor (TCR) sequencing from established T-cell lines was applied for neoepitope-specific TCR discovery. Efficacy of intravent…

Cancer ResearchT-LymphocytesT cellCellchemical and pharmacologic phenomenaRecurrent GliomaMajor histocompatibility complexImmunotherapy AdoptiveMiceGliomamedicineAnimalsMHC class IIReceptors Chimeric AntigenbiologyELISPOTT-cell receptorGliomamedicine.diseaseDisease Models Animalmedicine.anatomical_structureOncologybiology.proteinCancer researchImmunotherapyNeoplasm Recurrence LocalClinical Cancer Research
researchProduct

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

2002

We report here on 2 patients who received adjuvant vaccination with an HLA-A2- or HLA-A24-restricted tyrosinase peptide, respectively, and GM-CSF for frequently relapsing stage IV melanoma. Following resection of metastases and irradiation of brain metastases in 1 patient, both patients were without evidence of disease when receiving the first vaccination. While the patients had had 9 and 12, respectively, mostly s.c., relapses during the 3 years before vaccination, they experienced freedom from relapse for more than 2 years after vaccination. We found a T-cell response to the vaccine peptide in both patients in the peripheral blood by ex vivo IFN-gamma ELISPOT assay. The T-cell population …

Cancer ResearchTime FactorsCD3 Complexmedicine.medical_treatmentCD8 AntigensT-LymphocytesPopulationTyrosinase PeptideCancer VaccinesPolymerase Chain ReactionDisease-Free SurvivalEpitopesInterferon-gammaRecurrencemedicineHumansRNA MessengerNeoplasm MetastasiseducationMelanomaeducation.field_of_studybiologybusiness.industryBrain NeoplasmsMonophenol MonooxygenaseMelanomaELISPOTImmunotherapymedicine.diseaseFlow CytometryImmunohistochemistryVaccinationOncologyGranzymeImmunologybiology.proteinbusinessPeptidesCD8International journal of cancer
researchProduct

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma

2021

We evaluated the safety and immunogenicity of the BNT162b2 vaccine in 52 patients with multiple myeloma (MM). Median age was 71.3 (range, 39.6-90.8) years. 26 (50%) patients had received active treatment including an immunomodulatory drug (IMiD) (n=21), an anti-CD38 monoclonal antibody (n=11) and/or a proteasome inhibitor (n=4). 21 had received previous treatment interrupted at a median of 27.5 (range, 3.5-169.3) months before first vaccine inoculum. 5 patients had indolent untreated MM. 35 patients had a history of autologous hematopoietic cell transplantation (HSCT) performed at a median of 44.4 (range, 3.5-169.3) months before first vaccine inoculum. The vaccination was well tolerated wi…

Cancer Researchmedicine.medical_specialtybiologybusiness.industryImmunogenicityELISPOTHematologymedicine.diseaseGastroenterologyPoster PresentationsVaccinationTransplantationOncologyInternal medicinemedicinebiology.proteinSeroconversionAntibodybusinessAdverse effectMultiple myelomaClinical Lymphoma Myeloma and Leukemia
researchProduct

Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and match…

2011

Kaposi sarcoma (KS) might develop because of incompetent immune responses, both non-specifically and specifically against the KS-associated herpesvirus (KSHV). Peripheral blood mononuclear cells from 15 classic (non-AIDS) KS cases, 13 KSHV seropositives (without KS) and 15 KSHV-seronegative controls were tested for interferon-γ T-cell (enzyme-linked immunospot [Elispot]) responses to KSHV-latency-associated nuclear antigen (LANA), KSHV-K8.1 and CMV/Epstein-Barr virus (EBV) peptide pools. The forearm and thigh of each participant was also tested for delayed-type hypersensitivity (DTH) against common recall antigens. Groups were compared with Fisher exact test and multinomial logistic regress…

Cancer ResearchvirusesT-LymphocytesEnzyme-Linked Immunosorbent AssayBiologyAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataPeripheral blood mononuclear cellArticleInterferon-gammaViral ProteinsImmune systemAntigenInterferonmedicineHumansInterferon gammaHypersensitivity DelayedAntigens ViralSarcoma KaposiSicilyGlycoproteinsKSHV SicilyClassic Kaposi SarcomaELISPOTvirus diseasesNuclear ProteinsAntigens NuclearGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseVirologyImmunity InnateKaposi sarcoma; HHV8; ELISPOT; immune responseOncologyCase-Control StudiesImmunologyHerpesvirus 8 HumanLeukocytes MononuclearSarcomamedicine.drug
researchProduct

The Impact of Harmonization on ELISPOT Assay Performance

2011

During more than 25 years of application in immunological sciences, ELISPOT has been established as a routine, robust, versatile, and reliable assay. From basic research to clinical immune monitoring, ELISPOT is being used to address the quantification and (to a lesser extent) functional characterization of immune cells secreting different molecules in the context of health and disease, immune intervention, and therapy in humans and other species [Kalyuzhny (Ed.) (2005) Handbook of Elispot: methods and protocols, Vol. 302, Humana Press Inc., Totowa, NJ]. Over the last decade, ELISPOT assays have been increasingly implemented as an immune-monitoring tool in clinical trials [Schmittel et al. …

Clinical trialProtocol (science)business.industryELISPOTImmunologyImmune interventionMedicinechemical and pharmacologic phenomenaContext (language use)HarmonizationImmune monitoringbusinessVaccine efficacy
researchProduct

Response Determination Criteria for ELISPOT: Toward a Standard that Can Be Applied Across Laboratories

2011

ELISPOT assay readout is often dichomized as positive or negative responses according to prespecified criteria. However, these criteria can vary widely across institutions. The adoption of a common response criterion is a key step toward cross-laboratory comparability. This chapter describes the two main approaches to response determination, identifying the strengths and limitations of each. Nonparametric statistical tests and consideration of data quality are recommended and instructions provided for their ready implementation by nonstatisticians and statisticians alike.

Computer scienceELISPOTData qualityImmunologyMEDLINEKey (cryptography)EconometricsNonparametric statistics
researchProduct

QUALITATIVE MODELING OF CELL GROWTH PROCESSES

1988

In this paper we present a qualitative physics model to reason about cell growth processes and cell-drug interactions, to be used in the knowledge base of NEWCHEM, an expert system intended to guide experimentation in the design of new optimal protocols in cancer treatment, After a brief discussion of the contributions that artificial intelligence techniques could make in cancer research and a brief presentation of some currently developed expert systems, some details of the proposed model based on the Forbus and Kuipers approaches to qualitative physics are given and its implementation as a LISP program is briefly discussed.

Computer sciencebusiness.industryManagement sciencemedia_common.quotation_subjectcomputer.software_genreExpert systemCancer treatmentPresentationQualitative physicsKnowledge baseArtificial IntelligenceLispArtificial intelligencebusinesscomputercomputer.programming_languagemedia_commonApplied Artificial Intelligence
researchProduct

Epistemic governance in local policy debates : The case of entitlement to early childhood education and care in Finland

2019

In Finland, children below school age have enjoyed the right to attend subsidised full-time early childhood education and care (ECEC). However, the attendance rate in Finland is low in comparison to other Nordic countries. Furthermore, the entitlement was restricted to 20 h per week in 2016 unless the child’s parents work or study full-time or unless it is believed that the child will benefit from full-time ECEC. The debates concerning restrictions in ECEC entitlement in three municipal councils serve as the data for this study. By using the framework of epistemic governance, we identify three differing constructions of the ECEC’s societal functions in the municipal policy debates. The simi…

Cultural StudiesEarly childhood educationEconomic growthepistemic capitalvarhaiskasvatus050402 sociologySosiologia - SociologySociology and Political SciencepaikallishallintokunnallispolitiikkaeducationchildcarepäivähoitoEntitlementLocal policySosiaali- ja yhteiskuntapolitiikka - Social policypolitiikka0504 sociologyPolitical science050602 political science & public administrationsubjektiiviset oikeudetSchool age childAttendance rateCorporate governance05 social sciencesEpistemic governance0506 political sciencelastenhoitoearly childhood educationsubjektiivinen päivähoito-oikeusKasvatustieteet - Educational sciencespolicy
researchProduct